TIAMULINA HF
Get in touch with us!
Una visión general
Also known simply as minicycline, is an antibiotic of the tetracycline group. It is bacteriostatic, classified as a long-acting type (it achieves plasma activities 2-4 times higher than its congeners). Minocycline is frequently used for the treatment of acne vulgaris and rosacea.
- Product Type: Tetracycline Antibiotic
- CAS Number: 13614-98-7
- Common Indications: Acute Acne and rosacea
- Product Status: Commercial
- Available Grades: Non-Micronized
- Documentation: CEP, DMF, CoA, MSDS
Advantages
Efficacy:
Much higher therapeutic adherence
Very wide antibiotic spectrum of action
Activity against Neisseria meningitidis.
Used to treat multidrug-resistant.
Safety:
Better pharmacokinetic profile.
Longer half-life than Tetracycline.
FDA and European approval for the treatment of infections.
Low development of resistance in bacteria.
Finished
Dosage Forms
It is offered in diverse pharmaceutical forms, including oral administration (tablets or capsules), topical application, and injectable formulations:
Topical:
Aerosol, Foam 1.5% and 4% Base
Injectable:
Injection 100 mg Base/Vial
Oral:
Tablets:
50, 75 and 100 mg
Tablet, extended release:
45, 55, 65, 80, 90, 105, 115 and 135 mg
Hard capsules:
100 mg
Global market status
USD global market sales
in 2022.
of the worldwide sales in
the US market
of the tetracycline
market
Few API manufacturers to cover worldwide demand.
Our API
Minocycline
- Our API minocycline is manufactured in accordance with cGMP and stringent international quality standars.
Quality
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process, enabling us to achieve rigorous and stringent results in accordance with injectables parameters, even under aseptic conditions.
Samples availables
PATENT PROTECTION
